Ksaales's Comments RSS Syndication from SeekingAlpha.com http://seekingalpha.comuser/192580/comments http://seekingalpha.com/article/77022-myriad-options-on-alzheimers-disease?source=feed#comment-167004 167004 Flurizan is R-flurbiprofen - the single enantiomer of the racemate NSAID flurbiprofen. Flurbiprofen has substantial anti-inflammatory activity through COX (because of S-flurbiprofen), R-flurbiprofen does not.

www.pubmedcentral.nih....]]> Tue, 13 May 2008 15:25:25 -0400 Flurizan is R-flurbiprofen - the single enantiomer of the racemate NSAID flurbiprofen. Flurbiprofen has substantial anti-inflammatory activity through COX (because of S-flurbiprofen), R-flurbiprofen does not.

www.pubmedcentral.nih....]]> http://seekingalpha.com/article/77022-myriad-options-on-alzheimers-disease?source=feed#comment-166876 166876 Tue, 13 May 2008 12:15:03 -0400 http://seekingalpha.com/article/77022-myriad-options-on-alzheimers-disease?source=feed#comment-166845 166845 2. The dose of Flurizan that shows the effect seen in the phase 2 study is 1600 mg/day. This dose of Ibuprofen and the other NSAIDS that have been shown to have an effect on abeta42 would not be tolerable for any reasonable amount of time. In addition, the mouse model and cell model data show that Flurizan is more potent than any of the NSAIDS that also modulate gamma secretase, so it is likely that even higher doses would be needed for Ibuprofen and other NSAIDS. It is only because Flurizan is not a significant inhibitor of Cox that it is able to be given at such high doses over such a long period of time.

I agree with the first comment by Mudphud. This statement is completely misleading: "While this study does not mirror the Myriad study, it still gives valuable hints on the possible outcome. There were some hopes that anti-inflammatory compounds may have a role to play on the treatment of AD. It seems that is premature." This implies that Flurizan is working through an anti-inflammatory effect rather than a modulation of gamma secretase which these two compounds do not have. Only a subset of NSAIDS have this activity.

I am also optimistic about Bapineuzumab, however the phase 2 data is not yet available, so it's easy to be optimistic. It is also important to realize that the safety issues of this compound may be substantial, and again, having no data makes it easier to remain optimistic.]]> Tue, 13 May 2008 11:39:54 -0400 2. The dose of Flurizan that shows the effect seen in the phase 2 study is 1600 mg/day. This dose of Ibuprofen and the other NSAIDS that have been shown to have an effect on abeta42 would not be tolerable for any reasonable amount of time. In addition, the mouse model and cell model data show that Flurizan is more potent than any of the NSAIDS that also modulate gamma secretase, so it is likely that even higher doses would be needed for Ibuprofen and other NSAIDS. It is only because Flurizan is not a significant inhibitor of Cox that it is able to be given at such high doses over such a long period of time.

I agree with the first comment by Mudphud. This statement is completely misleading: "While this study does not mirror the Myriad study, it still gives valuable hints on the possible outcome. There were some hopes that anti-inflammatory compounds may have a role to play on the treatment of AD. It seems that is premature." This implies that Flurizan is working through an anti-inflammatory effect rather than a modulation of gamma secretase which these two compounds do not have. Only a subset of NSAIDS have this activity.

I am also optimistic about Bapineuzumab, however the phase 2 data is not yet available, so it's easy to be optimistic. It is also important to realize that the safety issues of this compound may be substantial, and again, having no data makes it easier to remain optimistic.]]>